20 Mar 2015
The discovery of effective anti-cancer drugs represents one of the greatest challenges to face humanity. There are more than 200 forms of cancer, each with different causes, symptoms and treatments. The rate of cancer diagnosis is rising fast – according to Cancer Research UK, someone in the UK is diagnosed with cancer every two minutes, with one in two people born after 1960 developing some form of cancer during their lifetime. Yet, at the same time, our ability to treat it has also improved, as 5-year cancer survival rates in the UK have doubled in the last forty years.
In his lecture on 29 April, Dr Michael J Waring, Principal Scientist in Medicinal Chemistry at AstraZeneca, will explain that whilst great progress has been made in both our understanding and our ability to discover new treatments for cancer, significant challenges remain.
Dr Waring will describe the role medicinal chemistry has played in the development of today's established treatments, modern approaches to targeted therapies and future challenges in tackling resistance to these therapies. He will showcase this with stories of how some of today's recognised drugs were discovered and how modern medicinal chemistry approaches have been applied to discover new treatments, which show great promise for the future.
The lecture will take place at the New York University in London, 6 Bedford Square and will be preceded by refreshments at 6pm. The lecture will begin at 6.15pm and will then be followed by an informal networking session with the speaker and fellow delegates.
This event is free, but space is limited, so early booking is advisable.
Please click on the link below for more information and how to book.
- Molecular Oncology - Past, Present and Future of Anti-Cancer Drug Design, 29 April 2015, New York University in London – book your place now
- SCI London Group